Home Administration of NivestimTM in the Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia

Inclusion Criteria: * Male and female patients ≥ 18 years * Declaration of informed consent signed by patient * Patients with a solid tumour or with a malignant haematological tumour * Patients who have been prescribed cytotoxic chemotherapy, irrespective of current cycle * GCSF-naïve patients or patients pre-treated with GCSF who received no GCSF in the last three months before enrolment * Patients starting primary prophylactic treatment using NivestimTM either to shorten the duration of a neutropenia or to prevent the occurrence of chemotherapy-induced FN Exclusion Criteria: * Patients with chronic myeloid leukaemia (CML) or with myelodysplastic syndrome (MDS) * Patients who are hypersensitive to one of the excipients of NivestimTM * Patients not undergoing chemotherapy * Patients being treated curatively or as secondary prophylaxis with G-CSF